Glucogast

Glucogast is a radiopharmaceutical containing the active ingredient fludeoxyglucose (18F) supplied as a sterile solution for injection. It is provided in a standard strength for intravenous administration and is prescribed by qualified healthcare professionals for diagnostic imaging in the European market. The product is classified under ATC code V09.10 and is used primarily in positron emission tomography (PET) procedures to visualize metabolic activity in various tissues.

Glucogast is indicated for several PET imaging applications where assessment of cellular glucose metabolism is required.

- Oncologic PET imaging to detect, stage, and monitor malignant tumors. - Cardiac PET imaging to evaluate myocardial viability and perfusion. - Neurologic PET imaging for assessment of epilepsy, dementia, and brain metabolism disorders. - Research studies investigating metabolic pathways or therapeutic response.

Adverse reactions to Glucogast are generally infrequent and related to the radiopharmaceutical nature of the product.

Common: - Transient flushing or warmth at the injection site. - Mild nausea or vomiting. - Short‑lasting headache. - Temporary metallic taste in the mouth.

Serious: - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Significant radiation‑induced tissue injury in rare cases. - Severe hypotension or cardiovascular collapse. - Persistent neurologic symptoms.

Use of Glucogast requires careful consideration of patient condition, radiation safety, and procedural factors.

- Verify pregnancy status; the radiopharmaceutical may pose fetal risk. - Assess renal function, as impaired clearance can increase radiation exposure. - Ensure adequate hydration before and after administration to promote tracer elimination. - Observe patients for immediate hypersensitivity reactions during and after injection. - Follow local radiation protection guidelines for staff and environment. - Avoid use in patients with uncontrolled diabetes unless glucose levels are appropriately managed.

Glucogast may interact with other agents that affect glucose metabolism or radiation exposure.

Avoid: - Concurrent administration of high‑dose glucose or insulin that could alter tracer distribution. - Use of other radiopharmaceuticals within 24 hours, which may increase cumulative radiation dose.

Use with caution: - Medications that cause vasodilation or hypotension, which may exacerbate rare cardiovascular reactions. - Contrast agents used in CT imaging performed immediately after PET, due to potential additive radiation. - Antihistamines or corticosteroids may mask early signs of an allergic response.